Incidence of hepatobiliary malignancies in primary sclerosing cholangitis: systematic review and meta-analysis.

Background And Aims: Primary sclerosing cholangitis (PSC) is a known risk factor for hepatobiliary malignancies. We conducted a systematic review and meta-analysis of published studies to determine the incidence and risk factors for hepatobiliary malignancies in people with PSC.

Methods: Pubmed and Embase databases were searched from inception to April 10, 2024 for cohort studies reporting data on the incidence of cholangiocarcinoma (CCA), hepatocellular carcinoma (HCC), or gallbladder cancer (GBC) in PSC.

High-grade biliary intraepithelial neoplasia localized in the distal bile duct diagnosed via peroral cholangioscopy: A rare case report.

Rationale: Biliary intraepithelial neoplasm (BilIN) is characterized by a microscopically identifiable preinvasive neoplasm of the biliary tract. BilIN is rarely diagnosed intentionally and is often detected incidentally in surgical specimens obtained via surgical resection for other types of cancers. Herein, we report a rare case of high-grade BilIN localized in the distal bile duct.

KLF5 silencing restrains proliferation, invasion, migration and angiogenesis of gallbladder carcinoma cells by transcriptional regulation of PDGFA.

Background: Krüppel-like factor 5 (KLF5) is recognized as a tumor mediator in multiple types of tumors. Nevertheless, whether KLF5 plays a role in gallbladder cancer (GBC) remains to be elucidated. This study aims to clarify the role of KLF5 in the proliferation, migration and angiogenesis in GBC cells.

Cutaneous Metastasis From Gallbladder Carcinoma: A Rare Case.

The occurrence of cutaneous metastasis from internal malignancies is relatively rare. Furthermore, cutaneous metastasis from gallbladder carcinoma is an infrequent phenomenon, with only a few reported cases. Here, we report a case of a 45-year-old male with cutaneous metastasis from primary gallbladder carcinoma, initially presenting solely with a scrotal lesion.

SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers.

Purpose: SWOG S1815 was a randomized, open label phase III trial, evaluating gemcitabine, nab-paclitaxel, and cisplatin (GAP) versus gemcitabine and cisplatin (GC) in patients with newly diagnosed advanced biliary tract cancers (BTCs).

Methods: Patients with newly diagnosed locally advanced unresectable or metastatic BTC, including intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) and gallbladder carcinoma (GBC), were randomly assigned 2:1 to either GAP (gemcitabine 800 mg/m, cisplatin 25 mg/m, and nab-paclitaxel 100 mg/m intravenously once per day on days 1 and 8 of a 21-day cycle) or GC (gemcitabine 1,000 mg/m and cisplatin 25 mg/m intravenously once per day on days 1 and 8 of a 21-day cycle).

Results: Among 452 randomly assigned participants, 441 were eligible and analyzable, 67% with ICC, 16% with GBC, and 17% with ECC.

Intracholecystic papillary neoplasm associated with an invasive carcinoma with cholecystocolonic fistula: a case report.

Intracholecystic papillary neoplasm and cholecystocolonic fistula are both relatively rare diseases. Here, we report a case of a preoperative intracholecystic papillary neoplasm associated with invasive carcinoma and a transverse colonic fistula of the gallbladder. A 79-year-old female patient presented to our hospital with persistent right upper quadrant pain for several months and was suspected to have intracholecystic papillary neoplasm associated with an invasive carcinoma by computed tomography and endoscopic ultrasound.

Primary Squamous Cell Carcinoma of the Gallbladder: Case Report.

Pure gallbladder squamous cell carcinoma is rare. Adenocarcinoma is the foremost malignant pathology of gallbladder cancer. Simultaneously, squamous cell carcinoma accounts for only 1% of malignant gallbladder tumors.

Chimeric Antigen Receptor (CAR)-T Cells: A New Era for Hepatocellular Carcinoma Treatment.

Hepatocellular carcinoma (HCC) is one of the most common cancers and a worldwide health concern that requires novel treatment approaches. Tyrosine kinase inhibitors (TKIs) and immune checkpoint blockades (ICBs) are the current standard of care; however, their clinical benefits are limited in some advanced and metastatic patients. With the help of gene engineering techniques, a novel adoptive cellular therapy (ACT) called chimeric antigen receptor (CAR)-T cells was recently introduced for treating HCC.

Efficacy of neoadjuvant therapy and lymph node dissection in advanced gallbladder cancer without distant metastases: a SEER database analysis.

Purpose: To investigate the effectiveness of neoadjuvant therapy and lymph node dissection(LND) on overall survival (OS) in patients with stage III/IV gallbladder cancer without distant metastases.

Methods: Data from 101 patients who received neoadjuvant therapy followed by surgery combined with adjuvant chemotherapy, and 1412 patients who received direct surgical treatment followed by adjuvant chemotherapy, were collected from the SEER database from 2004 to 2020. Patients were divided into group A (neoadjuvant therapy) and group B (direct surgery) based on the treatment modality.

The application of hepatopancreatoduodenectomy in advanced gallbladder carcinoma: Patients' selection, surgical outcome and influence on survival compared to radical cholecystectomy.

Aim: to investigate hepatopancreatoduodenectomy (HPD) application in gallbladder carcinoma (GBC) and compare it to radical cholecystectomy (RC) regarding patients' characteristics, surgical outcome and survival.

Methods: Patients treated in our center were included. Three groups (HPD, RC, no-surgery) were compared.

Endoscopic diagnosis and management of gallbladder carcinoma in minimally invasive era: New needs, new models.

Gallbladder cancer (GBC) is a rare and lethal malignancy; however, it represents the most common type of biliary tract cancer. Patients with GBC are often diagnosed at an advanced stage, thus, unfortunately, losing the opportunity for curative surgical intervention. This situation leads to lower quality of life and higher mortality rates.

SMARCA4-Deficient Undifferentiated Gallbladder Cancer: A Case Report and Review of the Literature.

Nonsense mutations or inactivation of (BRG1) are associated with the histological manifestations of many undifferentiated tumors in humans. However, the relationship between mutations and undifferentiated gallbladder cancer needs to be further elucidated. SMARCA4-deficient undifferentiated gallbladder cancer is a rare and highly malignant tumor.

Machine learning model for early prediction of survival in gallbladder adenocarcinoma: A comparison study.

The prognosis for gallbladder adenocarcinoma (GBAC), a highly malignant cancer, is not good. In order to facilitate individualized risk stratification and improve clinical decision-making, this study set out to create and validate a machine learning model that could accurately predict early survival outcomes in GBAC patients. Five models-RSF, Cox regression, GBM, XGBoost, and Deepsurv-were compared using data from the SEER database (2010-2020).